CDK8 and prostate cancer: Given that leukemic cells are sensitive to the dosage of super-enhancer-associated genes affected by CDK8/19 inhibition [21], the possibility exists that certain prostate cancer cells such as VCaP cells may also show vulnerability to the activation of super-enhancer-associated genes.